Cargando…

Pulmonary Vascular Disease Due to Plasma Cell Dyscrasia

Pulmonary hypertension (PH) has been described in myeloproliferative disorders; monoclonal plasma cell disorder such as polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes syndrome; and plasma cell dyscrasias such as multiple myeloma and amyloidosis. We describe 4 c...

Descripción completa

Detalles Bibliográficos
Autores principales: Rajapreyar, Indranee, Joly, Joanna, Tallaj, Jose, Pamboukian, Salpy V., Assad, Ayman Haj, Lenneman, Carrie, Litovsky, Silvio, Chatterjee, Arka, Hoopes, Charles, Lenneman, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7930784/
https://www.ncbi.nlm.nih.gov/pubmed/33718795
http://dx.doi.org/10.1016/j.mayocpiqo.2020.09.004
Descripción
Sumario:Pulmonary hypertension (PH) has been described in myeloproliferative disorders; monoclonal plasma cell disorder such as polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes syndrome; and plasma cell dyscrasias such as multiple myeloma and amyloidosis. We describe 4 cases of PH likely due to pulmonary vascular involvement and myocardial deposition from light chain deposition disease, amyloidosis, and multiple myeloma. On the basis of our clinical experience and literature review, we propose screening for plasma cell dyscrasia in patients with heart failure with preserved ejection fraction, unexplained PH, and hematological abnormalities. We also recommend inclusion of cardiopulmonary screening in patients with monoclonal gammopathy of undetermined significance.